Core Insights - Anhui Tongling Bionic Technology Co., Ltd. has completed a B+ round of financing, with the amount undisclosed, involving investors such as Zhenshi Capital and Wenzhi Capital [1][2]. Company Overview - Tongling Bionic is a provider of comprehensive solutions for heart failure throughout its lifecycle, focusing on integrated diagnosis and treatment solutions for heart failure patients [2]. - The company is engaged in the development of various innovative products for heart failure, including: - Invasive cardiac catheter pumps (pVAD) - Intra-aortic balloon pump systems (IABP) - External counterpulsation therapy systems - Non-invasive cardiac output monitoring devices - Extracorporeal membrane oxygenation devices (ECMO) [2].